Document ID: chunk:federal_register_of_legislation:F2025C00158:clause:4_1:p3
Version: federal_register_of_legislation:F2025C00158
Segment Type: clause
Provision Reference: sch 4 cl 1 (pt 3/191)
Character Range: 9481060–9492541

Patient must be scheduled to be administered a chemotherapy regimen that includes any 1 of the following agents:
                                                                                                                                                                                                                                altretamine; carmustine; cisplatin when a single dose constitutes a cycle of chemotherapy; cyclophosphamide at a dose of 1500 mg per square metre per day or greater; dacarbazine; procarbazine when a single dose constitutes a cycle of chemotherapy; streptozocin.
                                                                                                                                                                                                                               No more than 1 capsule of aprepitant 165 mg will be authorised per cycle of cytotoxic chemotherapy.
C4215               P4215          CN4215           Aprepitant                                                                                                                                                                 Nausea and vomiting                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Compliance with Authority Required procedures - Streamlined Authority Code 4215
                                                                                                                                                                                                                               The condition must be associated with cytotoxic chemotherapy being used to treat breast cancer; AND
                                                                                                                                                                                                                               The treatment must be in combination with a 5-hydroxytryptamine receptor (5HT3) antagonist and dexamethasone; AND
                                                                                                                                                                                                                               Patient must be scheduled to be co-administered cyclophosphamide and an anthracycline.
                                                                                                                                                                                                                               No more than 1 capsule of aprepitant 165 mg will be authorised per cycle of cytotoxic chemotherapy.
C4216               P4216          CN4216           Aprepitant                                                                                                                                                                 Nausea and vomiting                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Compliance with Authority Required procedures - Streamlined Authority Code 4216
                                                                                                                                                                                                                               The condition must be associated with cytotoxic chemotherapy being used to treat breast cancer; AND
                                                                                                                                                                                                                               The treatment must be in combination with a 5-hydroxytryptamine receptor (5HT3) antagonist and dexamethasone; AND
                                                                                                                                                                                                                               Patient must be scheduled to be co-administered cyclophosphamide and an anthracycline.
                                                                                                                                                                                                                               No more than 1 capsule of aprepitant 165 mg will be authorised per cycle of cytotoxic chemotherapy.
C4223               P4223          CN4223           Aprepitant                                                                                                                                                                 Nausea and vomiting                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Compliance with Authority Required procedures - Streamlined Authority Code 4223
                                                                                                                                                                                                                               The condition must be associated with cytotoxic chemotherapy being used to treat malignancy; AND
                                                                                                                                                                                                                               The treatment must be in combination with a 5-hydroxytryptamine receptor (5HT3) antagonist and dexamethasone; AND
                                                                                                                                                                                                                               Patient must be scheduled to be administered a chemotherapy regimen that includes any 1 of the following agents:
                                                                                                                                                                                                                                altretamine; carmustine; cisplatin when a single dose constitutes a cycle of chemotherapy; cyclophosphamide at a dose of 1500 mg per square metre per day or greater; dacarbazine; procarbazine when a single dose constitutes a cycle of chemotherapy; streptozocin.
                                                                                                                                                                                                                               No more than 1 capsule of aprepitant 165 mg will be authorised per cycle of cytotoxic chemotherapy.
C4229               P4229          CN4229           Imiquimod                                                                                                                                                                  Superficial basal cell carcinoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Compliance with Authority Required procedures
                                                                                                                                                                                                                               The condition must be previously untreated; AND
                                                                                                                                                                                                                               The condition must be confirmed by biopsy; AND
                                                                                                                                                                                                                               Patient must have normal immune function; AND
                                                                                                                                                                                                                               The condition must not be suitable for treatment with surgical excision; or
                                                                                                                                                                                                                               The condition must not be suitable for treatment with cryotherapy; or
                                                                                                                                                                                                                               The condition must not be suitable for treatment with curettage with diathermy; AND
                                                                                                                                                                                                                               Patient must require topical drug therapy.
                                                                                                                                                                                                                               The date of the pathology report and name of the Approved Pathology Authority must be provided at the time of application.
C4242               P4242          CN4242           Vinorelbine                                                                                                                                                                Locally advanced or metastatic non-small cell